Oncotarget

Research Papers:

Luminal B breast cancer: patterns of recurrence and clinical outcome

Zhi-hua Li _, Ping-hua Hu, Jian-hong Tu and Ni-si Yu

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:65024-65033. https://doi.org/10.18632/oncotarget.11344

Metrics: PDF 1077 views  |   HTML 1936 views  |   ?  


Abstract

Zhi-hua Li1, Ping-hua Hu1, Jian-hong Tu2, Ni-si Yu3

1Prevention and Cure Center of Breast Disease, The Third Hospital of Nanchang City, Key Laboratory Of Breast Diseases In Jiangxi Province, Nanchang, JiangXi 330009, People’s Republic of China

2Department of Pathology, The Third Hospital of Nanchang City, JiangXi Breast Specialist Hospital, Nanchang, JiangXi 330009, People’s Republic of China

3Department of Gynaecology, The Affiliated Hospital of Jiangxi Traditional Chinese Medicine University, Nanchang, Jiangxi 330006, People’s Republic of China

Correspondence to:

Zhi-hua Li, email: huazhili0802@163.com

Keywords: luminal B subtype, breast cancer, recurrence pattern, prognosis

Received: April 18, 2016     Accepted: July 28, 2016     Published: August 17, 2016

ABSTRACT

In recent years, most studies on breast cancer relapse and metastasis have focused on non-luminal breast cancers (including the basal-like and HER-2 subtypes) because of their poor prognosis. However, the luminal B subtype is more common, but this type has not been investigated as thoroughly. In the current study, we collected data on 258 patients with luminal-B breast cancer patients with recurrence and metastasis served as the observation group, and 189 patients with non-luminal breast cancer during the same period served as the control group. This study aimed to investigate the pattern of recurrence and clinical outcome after follow-up treatment for luminal B breast cancer. We found a higher proportion of local recurrence and single bone metastasis in patients with luminal B breast cancer than in patients in the non-luminal groups. The risk of recurrence and metastasis in patients with luminal B breast cancer during a 2- to 5-year period and after 5 years was still present, but the risk in patients with non-luminal breast cancers had obviously decreased during the same period. Patients with luminal B breast cancer with recurrence or/and metastasis had a better prognosis after reasonable treatment. The recurrence patterns and clinical outcomes of patients with luminal B breast cancer according to HER2 status were also different, to some degree. These results are of potential clinical relevance especially for the monitoring of clinical prognosis and targeted therapy intervention for luminal B breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11344